Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA OKs 1st Over-the-Counter Weight-Loss Drug

Alli only works when used with a diet and exercise program

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Ankle Sprains
Antioxidants
More...

Related Healthscout Videos
 border=
Hungry Heart
Power Out Fat
Soy - Many Forms, Many Benefits
Soy - Health Benefits Explained
More...

Related Drug Information
 border=
Klor-Con
Klor-Con ER
More...

Related News Articles
 border=
FDA Warns Epilepsy Drugs May Raise Suicide Risk
Quit-Smoking Drug May Raise Suicide Risk
Folic Acid May Help Prevent Premature Birth
Atkins-Like Diet Cuts Epileptic Seizures
More...

WEDNESDAY, Feb. 7 (HealthDay News) -- The first nonprescription drug to treat obesity in American adults was approved Wednesday by the U.S. Food and Drug Administration.

The drug, called alli (orlistat), is designed to be used only in tandem with a reduced-calorie, low-fat diet by overweight adults aged 18 and older. According to manufacturer GlaxoSmithKline, the drug helps people lose 50 percent more weight than dieting alone, should cost consumers $12 to $25 a week, and is expected to be available by this summer.

Text Continues Below



"This is the only FDA-approved, over-the-counter weight-loss drug product," Dr. Charles J. Ganley, the FDA's director of the Division of Over-The-Counter Drug Products, said during a teleconference. "There are some products, primarily dietary supplements, that make weight-loss claims and those are not FDA-approved, although they are permitted to make these claims."

The drug will be available in 60 milligram capsules, to be taken three times a day with meals that contain fat. The company said the drug works by "blocking about 25 percent of the fat in food a person eats. Because of the way it works, alli must be used in conjunction with a reduced-calorie, low-fat diet containing about 15 grams of fat per meal."

Eating a meal with too much fat while taking the drug can result in bowel changes such as loose stools, according to the FDA. These side effects typically occur in the first weeks of treatment, they aren't harmful, and can be managed by following the recommended diet of about 15 grams of fat per meal, GlaxoSmithKline said.

It's also recommended that users take a multivitamin once a day, at bedtime, because the drug can interfere with the absorption of some vitamins, GlaxoSmithKline said.

People who have had an organ transplant shouldn't take the drug. And anyone taking blood-thinning medicines or being treated for diabetes or thyroid disease should consult a physician before using the drug, the FDA said.

Page:  1 | 2 | 3 | Next >>

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 2/8/2007

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





New Features

New ADHD Site!

SOURCES: Feb. 7, 2007, U.S. Food and Drug Administration teleconference with Charles J. Ganley, M.D., director, Division of Over-The-Counter Drug Products, Washington, D.C.; Raj Padwal, M.D., assistant professor, general internal medicine, University of Alberta, Edmonton, Canada; David L. Katz, M.D., associate professor, public health, and director, Prevention Research Center, Yale University School of Medicine, New Haven, Conn.


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map